ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2026-1-163-175ssmu-6416Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESПротеомные исследования при коронарном атеросклерозеProteomic studies in coronary atherosclerosishttps://orcid.org/0000-0003-0484-6540СтахнёваЕ. М.StakhnevaE. M.

Стахнёва Екатерина Михайловна – канд. биол. наук, ст. науч. сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний

Россия, 630089, г. Новосибирск, ул. Богаткова, 175/1

175/1 Bogatkov St., 630089 Novosibirsk, Russian Federation

stahneva@yandex.ruhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoYu. I.

Рагино Юлия Игоревна – д-р мед. наук, профессор, член-корр. РАН, гл. науч. сотрудник, руководитель

Россия, 630089, г. Новосибирск, ул. Богаткова, 175/1

175/1 Bogatkov St., 630089 Novosibirsk, Russian Federation

ragino@mail.ruhttps://orcid.org/0000-0003-2268-4186КаштановаЕ. В.KashtanovaE. V.

Каштанова Елена Владимировна – д-р биол. наук, вед. науч. сотрудник, зав. лабораторией клинических биохимических и гормональных исследований терапевтических заболеваний

Россия, 630089, г. Новосибирск, ул. Богаткова, 175/1

175/1 Bogatkov St., 630089 Novosibirsk, Russian Federation

elekastanova@yandex.ruhttps://orcid.org/0000-0002-3538-0280ПолонскаяЯ. В.PolonskayaYa. V.

Полонская Яна Владимировна – д-р биол. наук, ст. науч. сотрудник, лаборатория клинических биохимических и гормональных исследований  терапевтических заболеваний

Россия, 630089, г. Новосибирск, ул. Богаткова, 175/1

175/1 Bogatkov St., 630089 Novosibirsk, Russian Federation

yana-polonskaya@yandex.ruНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального исследовательского центра «Институт цитологии и генетики СО РАН» (НИИТПМ – филиал ИЦиГ СО РАН)РоссияResearch Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of SciencesRussian Federation202613042026251163175Copyright © Стахнёва Е.М., Рагино Ю.И., Каштанова Е.В., Полонская Я.В., 20262026Стахнёва Е.М., Рагино Ю.И., Каштанова Е.В., Полонская Я.В.Stakhneva E.M., Ragino Y.I., Kashtanova E.V., Polonskaya Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/6416

Протеомные исследования внесли существенный вклад в изучение патогенеза сердечно-сосудистых заболеваний, создавая основу для разработки новых потенциальных биомаркеров оценки риска развития заболеваний и их осложнений.Цель исследования: обобщить имеющиеся данные о протеомных исследованиях в области сердечно-сосудистых заболеваний атеросклеротического генеза и коронарного атеросклероза. Проведен анализ основных зарубежных и отечественных источников преимущественно за последние 15 лет по базам данных PubMed/Medline, РИНЦ/ELIBRARY.RU. Приоритет был отдан исследованиям по поиску новых протеомных биомаркеров коронарного атеросклероза, в том числе протеомных маркеров нестабильной атеросклеротической бляшки. Приведены данные собственных протеомных исследований потенциальных биомаркеров в области коронарного атеросклероза.

Proteomic studies have made a significant contribution to the study of the pathogenesis of cardiovascular diseases, creating the basis for the development of new potential biomarkers for assessing the risk of developing diseases and their complications. We analyzed the main foreign and domestic publications over the past 15 years using the PubMed/Medline and RSCI/elibrary.ru databases and summarized the available data on proteomic studies in the field of atherosclerotic cardiovascular diseases and coronary atherosclerosis. In this literature review, priority was given to studies on the search for new proteomic biomarkers of coronary atherosclerosis, including proteomic markers of unstable atherosclerotic plaques. The data from our own proteomic studies on potential biomarkers of coronary atherosclerosis are presented.

атеросклерозпротеомикамасс-спектрометриябиомаркерымакрофагиatherosclerosisproteomicsmass spectrometrybiomarkersmacrophagesРабота выполнена в рамках бюджетной темы по государственному заданию № FWNR-2024-0004.ReferencesWolf D., Ley K. Immunity and inflammation in atherosclerosis. Circ. Res. 2019;124(2):315–327. DOI: 10.1161/CIRCRESAHA.118.313591.Wolf D., Ley K. Immunity and inflammation in atherosclerosis. Circ. Res. 2019;124(2):315–327. DOI: 10.1161/CIRCRESAHA.118.313591.Tsao C.W., Aday A.W., Almarzooq Z.I. Alonso A., Beaton A.Z., Bittencourt M.S. et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. DOI: 10.1161/CIR.0000000000001052.Tsao C.W., Aday A.W., Almarzooq Z.I. Alonso A., Beaton A.Z., Bittencourt M.S. et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. DOI: 10.1161/CIR.0000000000001052.Bobryshev Y.V. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37:208–222. DOI: 10.1016/j.micron.2005.10.00.Bobryshev Y.V. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37:208–222. DOI: 10.1016/j.micron.2005.10.00.Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014;114(12):1852–1866. DOI: 10.1161/CIRCRESAHA.114.302721.Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014;114(12):1852–1866. DOI: 10.1161/CIRCRESAHA.114.302721.Mohamed Bakrim N., Mohd Shah A.N.S., Talib N.A., Ab Rahman J., Abdullah A. Identification of haptoglobin as a potential biomarker in young adults with acute myocardial infarction by proteomic analysis. Malays. J. Med. Sci. 2020;27(2):64–76. DOI: 10.21315/mjms2020.27.2.8.Mohamed Bakrim N., Mohd Shah A.N.S., Talib N.A., Ab Rahman J., Abdullah A. Identification of haptoglobin as a potential biomarker in young adults with acute myocardial infarction by proteomic analysis. Malays. J. Med. Sci. 2020;27(2):64–76. DOI: 10.21315/mjms2020.27.2.8.Navas-Carrillo D., Marín F., Valdés M., Orenes-Piñero E. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles. Crit. Rev. Clin. Lab. Sci. 2017;54(1):49–58. DOI: 10.1080/10408363.2016.1241214.Navas-Carrillo D., Marín F., Valdés M., Orenes-Piñero E. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles. Crit. Rev. Clin. Lab. Sci. 2017;54(1):49–58. DOI: 10.1080/10408363.2016.1241214.Stöhr R., Schurgers L., van Gorp R., Jaminon A., Marx N. Reutelingsperger C. Annexin A5 reduces early plaque formation in ApoE –/– mice. PLoS One. 2017;12(12):e0190229. DOI: 10.1371/journal.pone.0190229.Stöhr R., Schurgers L., van Gorp R., Jaminon A., Marx N. Reutelingsperger C. Annexin A5 reduces early plaque formation in ApoE –/– mice. PLoS One. 2017;12(12):e0190229. DOI: 10.1371/journal.pone.0190229.Bagnato C., Thumar J., Mayya V., Hwang S.I., Zebroski H., Claffey K.P. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol. Cell Proteomics. 2007;6(6):1088–1102. DOI: 10.1074/mcp.M600259-MCP200.Bagnato C., Thumar J., Mayya V., Hwang S.I., Zebroski H., Claffey K.P. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol. Cell Proteomics. 2007;6(6):1088–1102. DOI: 10.1074/mcp.M600259-MCP200.Zhou Y., Yuan J., Fan Y., An F., Chen J., Zhang Y. et al. Proteomic landscape of human coronary artery atherosclerosis. Int. J. Mol. Med. 2020;46(1):371–383. DOI: 10.3892/ijmm.2020.4600.Zhou Y., Yuan J., Fan Y., An F., Chen J., Zhang Y. et al. Proteomic landscape of human coronary artery atherosclerosis. Int. J. Mol. Med. 2020;46(1):371–383. DOI: 10.3892/ijmm.2020.4600.Malaud E., Merle D., Piquer D., Molina L., Salvetat N., Rubrecht L. et al. Local carotid atherosclerotic plaque proteins for the identification of circulating biomarkers in coronary patients. Atherosclerosis. 2014;233(2):551–558. DOI: 10.1016/j.atherosclerosis.2013.12.019.Malaud E., Merle D., Piquer D., Molina L., Salvetat N., Rubrecht L. et al. Local carotid atherosclerotic plaque proteins for the identification of circulating biomarkers in coronary patients. Atherosclerosis. 2014;233(2):551–558. DOI: 10.1016/j.atherosclerosis.2013.12.019.Lee R., Fischer R., Charles P.D., Adlam D., Valli A., Di Gleria K. et al. A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption. Clin. Proteomics. 2017;14:22. DOI: 10.1186/ s12014-017-9157-x.Lee R., Fischer R., Charles P.D., Adlam D., Valli A., Di Gleria K. et al. A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption. Clin. Proteomics. 2017;14:22. DOI: 10.1186/ s12014-017-9157-x.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Sadovski E.V., Peltek S.E. et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis. Diagnostics. 2019;9(4):177. DOI: 10.3390/diagnostics9040177.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Sadovski E.V., Peltek S.E. et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis. Diagnostics. 2019;9(4):177. DOI: 10.3390/diagnostics9040177.Herrington D.M., Mao C., Parker S.J., Fu Z., Yu G., Chen L. et al. Proteomic architecture of human coronary and aortic atherosclerosis. Circulation. 2018;137(25):2741–2756. DOI: 10.1161/CIRCULATIONAHA.118.034365.Herrington D.M., Mao C., Parker S.J., Fu Z., Yu G., Chen L. et al. Proteomic architecture of human coronary and aortic atherosclerosis. Circulation. 2018;137(25):2741–2756. DOI: 10.1161/CIRCULATIONAHA.118.034365.Han Y., Zhao S., Gong Y., Hou G., Li X., Li L. Serum cyclin-dependent kinase 9 is a potential biomark- er of atherosclerotic inflammation. Oncotarget. 2016;7(2):1854–1862. DOI: 10.18632/ oncotarget.6443.Han Y., Zhao S., Gong Y., Hou G., Li X., Li L. Serum cyclin-dependent kinase 9 is a potential biomark- er of atherosclerotic inflammation. Oncotarget. 2016;7(2):1854–1862. DOI: 10.18632/ oncotarget.6443.Lepedda A.J., Cigliano A., Cherchi G.M., Spirito R., Maggioni M., Carta F. et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis. 2009;203(1):112–118. DOI: 10.1016/j.atherosclerosis.2008.07.001.Lepedda A.J., Cigliano A., Cherchi G.M., Spirito R., Maggioni M., Carta F. et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis. 2009;203(1):112–118. DOI: 10.1016/j.atherosclerosis.2008.07.001.Olson F.J., Sihlbom C., Davidsson P., Hulthe J., Fagerberg B., Bergström G. Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques. Biochem. Biophys. Res. Commun. 2010;401(4):574–580. DOI: 10.1016/j.bbrc.2010.09.103.Olson F.J., Sihlbom C., Davidsson P., Hulthe J., Fagerberg B., Bergström G. Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques. Biochem. Biophys. Res. Commun. 2010;401(4):574–580. DOI: 10.1016/j.bbrc.2010.09.103.Rocchiccioli S., Pelosi G., Rosini S., Marconi M., Viglione F., Citti L. et al. Secreted proteins from carotid endarterectomy: an untargeted approach to disclose molecular clues of plaque progression. J. Transl. Med. 2013;11:260. DOI: 10.1186/1479-5876-11-260.Rocchiccioli S., Pelosi G., Rosini S., Marconi M., Viglione F., Citti L. et al. Secreted proteins from carotid endarterectomy: an untargeted approach to disclose molecular clues of plaque progression. J. Transl. Med. 2013;11:260. DOI: 10.1186/1479-5876-11-260.Seki T., Saita E., Kishimoto Y., Ibe S., Miyazaki Y., Miura K. et al. Low levels of plasma osteoglycin in patients with complex coronary lesions. J. Atheroscler. Thromb. 2018;25(11):1149–1155. DOI: 10.5551/jat.43059.Seki T., Saita E., Kishimoto Y., Ibe S., Miyazaki Y., Miura K. et al. Low levels of plasma osteoglycin in patients with complex coronary lesions. J. Atheroscler. Thromb. 2018;25(11):1149–1155. DOI: 10.5551/jat.43059.Cheng J.M., Akkerhuis K.M., Meilhac O., Oemrawsingh R.M., Garcia-Garcia H.M., van Geuns R.J. et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler. Thromb. Vasc. Biol. 2014;34(5):1078–1084. DOI: 10.1161/ATVBAHA.114.303486.Cheng J.M., Akkerhuis K.M., Meilhac O., Oemrawsingh R.M., Garcia-Garcia H.M., van Geuns R.J. et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler. Thromb. Vasc. Biol. 2014;34(5):1078–1084. DOI: 10.1161/ATVBAHA.114.303486.Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Endothelial barrier and its abnormalities in cardiovascular disease. Front. Physiol. 2015;6:365. DOI: 10.3389/fphys.2015.00365.Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Endothelial barrier and its abnormalities in cardiovascular disease. Front. Physiol. 2015;6:365. DOI: 10.3389/fphys.2015.00365.Tu Z.L., Yu B., Huang D.Y., Ojha R., Zhou S.K., An H.D. et al. Proteomic analysis and comparison of intra- and extracranial cerebral atherosclerosis responses to hyperlipidemia in rabbits. Mol. Med. Rep. 2017;16(3):2347–2354. DOI: 10.3892/mmr.2017.6869.Tu Z.L., Yu B., Huang D.Y., Ojha R., Zhou S.K., An H.D. et al. Proteomic analysis and comparison of intra- and extracranial cerebral atherosclerosis responses to hyperlipidemia in rabbits. Mol. Med. Rep. 2017;16(3):2347–2354. DOI: 10.3892/mmr.2017.6869.Matyushenko A.M., Koubassova N.A., Shchepkin D.V., Kopylova G.V., Nabiev S.R., Nikitina L.V. et al. The effects of cardiomyopathy-associated mutations in the head-to-tail overlap junction of α-tropomyosin on its properties and interaction with actin. Int. J. Biol. Macromol. 2019;125:1266–1274. DOI: 10.1016/j.ijbiomac.2018.09.105.Matyushenko A.M., Koubassova N.A., Shchepkin D.V., Kopylova G.V., Nabiev S.R., Nikitina L.V. et al. The effects of cardiomyopathy-associated mutations in the head-to-tail overlap junction of α-tropomyosin on its properties and interaction with actin. Int. J. Biol. Macromol. 2019;125:1266–1274. DOI: 10.1016/j.ijbiomac.2018.09.105.Dirajlal-Fargo S., Kulkarni M., Bowman E., Shan L., Sattar A., Funderburg N. et al. Serum albumin is associated with higher inflammation and carotid atherosclerosis in treated human immunodeficiency virus infection. Open Forum Infect. Dis. 2018;5(11):ofy291. DOI: 10.1093/ofid/ofy291.Dirajlal-Fargo S., Kulkarni M., Bowman E., Shan L., Sattar A., Funderburg N. et al. Serum albumin is associated with higher inflammation and carotid atherosclerosis in treated human immunodeficiency virus infection. Open Forum Infect. Dis. 2018;5(11):ofy291. DOI: 10.1093/ofid/ofy291.Lin P., Ji H.H., Li Y.J., Guo S.D. Macrophage plasticity and atherosclerosis therapy. Front. Mol. Biosci. 2021;8:679797. DOI: 10.3389/fmolb.2021.679797.Lin P., Ji H.H., Li Y.J., Guo S.D. Macrophage plasticity and atherosclerosis therapy. Front. Mol. Biosci. 2021;8:679797. DOI: 10.3389/fmolb.2021.679797.Gordon S., Martinez F.O. Alternative activation of macrophages: Mechanism and functions. Immunity. 2010;32(5):593–604. DOI: 10.1016/j.immuni.2010.05.007.Gordon S., Martinez F.O. Alternative activation of macrophages: Mechanism and functions. Immunity. 2010;32(5):593–604. DOI: 10.1016/j.immuni.2010.05.007.Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11(11):723–737. DOI: 10.1038/nri3073.Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11(11):723–737. DOI: 10.1038/nri3073.Wang L.X., Zhang S.X., Wu H.J., Rong X.L., Guo J. M2b macrophage polarization and its roles in diseases. J. Leukoc. Biol. 2019;106(2):345–358. DOI: 10.1002/JLB.3RU1018-378RR.Wang L.X., Zhang S.X., Wu H.J., Rong X.L., Guo J. M2b macrophage polarization and its roles in diseases. J. Leukoc. Biol. 2019;106(2):345–358. DOI: 10.1002/JLB.3RU1018-378RR.Zizzo G., Hilliard B.A., Monestier M., Cohen P.L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J. Immunol. 2012;189(7):3508–3520. DOI: 10.4049/jimmunol.1200662.Zizzo G., Hilliard B.A., Monestier M., Cohen P.L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J. Immunol. 2012;189(7):3508–3520. DOI: 10.4049/jimmunol.1200662.Ferrante C.J., Pinhal-Enfield G., Elson G., Cronstein B.N., Hasko G., Outram S., Leibovich S.J. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation. 2013;36(4):921–931. DOI: 10.1007/s10753-013-9621-3.Ferrante C.J., Pinhal-Enfield G., Elson G., Cronstein B.N., Hasko G., Outram S., Leibovich S.J. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation. 2013;36(4):921–931. DOI: 10.1007/s10753-013-9621-3.Nielsen M.J., Moller H.J., Moestrup S.K. Hemoglobin and heme scavenger receptors. Antioxid. Redox. Signal. 2010;12(2):261–273. DOI: 10.1089/ars.2009.2792.Nielsen M.J., Moller H.J., Moestrup S.K. Hemoglobin and heme scavenger receptors. Antioxid. Redox. Signal. 2010;12(2):261–273. DOI: 10.1089/ars.2009.2792.Boyle J.J. Heme and haemoglobin direct macrophage Mhem phenotype and counter foam cell formation in areas of intraplaque haemorrhage. Curr. Opin. Lipidol. 2012;23(5):453–461. DOI: 10.1097/MOL.0b013e328356b145.Boyle J.J. Heme and haemoglobin direct macrophage Mhem phenotype and counter foam cell formation in areas of intraplaque haemorrhage. Curr. Opin. Lipidol. 2012;23(5):453–461. DOI: 10.1097/MOL.0b013e328356b145.Boyle J.J., Johns M., Kampfer T., Nguyen A.T., Game L., Schaer D.J. et al. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ. Res. 2012;110(1):20–33. DOI: 10.1161/CIRCRESAHA.111.247577.Boyle J.J., Johns M., Kampfer T., Nguyen A.T., Game L., Schaer D.J. et al. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ. Res. 2012;110(1):20–33. DOI: 10.1161/CIRCRESAHA.111.247577.Stoger J.L., Gijbels M.J., van der Velden S., Nguyen A.T., Game L., Schaer D.J. et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461–468. DOI: 10.1016/j.atherosclerosis.2012.09.013.Stoger J.L., Gijbels M.J., van der Velden S., Nguyen A.T., Game L., Schaer D.J. et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461–468. DOI: 10.1016/j.atherosclerosis.2012.09.013.Cho K.Y., Miyoshi H., Kuroda S., Yasuda H., Kamiyama K., Nakagawara J. et al. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J. Stroke Cereb. Dis. 2013;22(7):910–918. DOI: 10.1016/j.jstrokecerebrovasdis.2012.11.020.Cho K.Y., Miyoshi H., Kuroda S., Yasuda H., Kamiyama K., Nakagawara J. et al. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J. Stroke Cereb. Dis. 2013;22(7):910–918. DOI: 10.1016/j.jstrokecerebrovasdis.2012.11.020.Chinetti-Gbaguidi G., Colin S., Staels B. Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 2015;12(1):10–17. DOI: 10.1038/nrcardio.2014.173.Chinetti-Gbaguidi G., Colin S., Staels B. Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 2015;12(1):10–17. DOI: 10.1038/nrcardio.2014.173.Barrett T.J. Macrophages in atherosclerosis regression. Arter. Thromb. Vasc. Biol. 2020;40(1):20–33. DOI: 10.1161/ATVBAHA.119.312802.Barrett T.J. Macrophages in atherosclerosis regression. Arter. Thromb. Vasc. Biol. 2020;40(1):20–33. DOI: 10.1161/ATVBAHA.119.312802.De Gaetano M., Crean D., Barry M., Belton O. M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis. Front. Immunol. 2016;7:275. DOI: 10.3389/fimmu.2016.00275.De Gaetano M., Crean D., Barry M., Belton O. M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis. Front. Immunol. 2016;7:275. DOI: 10.3389/fimmu.2016.00275.Vaisar T., Hu J.H., Airhart N., Fox K., Heinecke J., Nicosia R.F. et al. Parallel murine and human plaque proteomics reveals pathways of plaque rupture. Circ. Res. 2020;127(8):997–1022. DOI: 10.1161/CIRCRESAHA.120.317295.Vaisar T., Hu J.H., Airhart N., Fox K., Heinecke J., Nicosia R.F. et al. Parallel murine and human plaque proteomics reveals pathways of plaque rupture. Circ. Res. 2020;127(8):997–1022. DOI: 10.1161/CIRCRESAHA.120.317295.Baetta R., Banfi C. Dkk (dickkopf) proteins. Arter. Thromb. Vasc. Biol. 2019;39(7):1330–1342. DOI: 10.1161/ATVBAHA.119.312612.Baetta R., Banfi C. Dkk (dickkopf) proteins. Arter. Thromb. Vasc. Biol. 2019;39(7):1330–1342. DOI: 10.1161/ATVBAHA.119.312612.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Peltek S.E., Voevoda M.I., Ragino Y.I. Changes in the proteomic profile of blood serum in coronary atherosclerosis. J. Med. Biochem. 2020;39(2):208–214. DOI: 10.2478/jomb-2019-0022.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Peltek S.E., Voevoda M.I., Ragino Y.I. Changes in the proteomic profile of blood serum in coronary atherosclerosis. J. Med. Biochem. 2020;39(2):208–214. DOI: 10.2478/jomb-2019-0022.Patzelt J., Verschoor A., Langer H.F. Platelets and the complement cascade in atherosclerosis. Front. Physiol. 2015;6:49. DOI: 10.3389/fphys.2015.00049.Patzelt J., Verschoor A., Langer H.F. Platelets and the complement cascade in atherosclerosis. Front. Physiol. 2015;6:49. DOI: 10.3389/fphys.2015.00049.Teoh C.L., Griffin M.D., Howlett G.J. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell. 2011;2(2):116–127. DOI: /10.1007/s13238-011-1013-6.Teoh C.L., Griffin M.D., Howlett G.J. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell. 2011;2(2):116–127. DOI: /10.1007/s13238-011-1013-6.Cubedo J., Padró T., Alonso R., Cinca J., Mata P., Badimon L. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis. 2012;222(1):263–269. DOI: 10.1016/j.atherosclerosis.2012.02.024.Cubedo J., Padró T., Alonso R., Cinca J., Mata P., Badimon L. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis. 2012;222(1):263–269. DOI: 10.1016/j.atherosclerosis.2012.02.024.Li F., Xia K., Li C., Yang T. Retinol-binding protein 4 as a novel risk factor for cardiovascular disease in patients with coronary artery disease and hyperinsulinemia. Am. J. Med. Sci. 2014;348(6):474–479. DOI: 10.1097/MAJ.0000000000000347.Li F., Xia K., Li C., Yang T. Retinol-binding protein 4 as a novel risk factor for cardiovascular disease in patients with coronary artery disease and hyperinsulinemia. Am. J. Med. Sci. 2014;348(6):474–479. DOI: 10.1097/MAJ.0000000000000347.Lambadiari V., Kadoglou N.P., Stasinos V., Maratou E., Antoniadis A., Kolokathis F. et al. Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovasc. Diabetol. 2014;13:121. DOI: 10.1186/s12933-014-0121-z.Lambadiari V., Kadoglou N.P., Stasinos V., Maratou E., Antoniadis A., Kolokathis F. et al. Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovasc. Diabetol. 2014;13:121. DOI: 10.1186/s12933-014-0121-z.Vinchi F., Muckenthaler M.U., Da Silva M.C., Balla G., Balla J., Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front. Pharmacol. 2014;5:94. DOI: 10.3389/fphar.2014.00094.Vinchi F., Muckenthaler M.U., Da Silva M.C., Balla G., Balla J., Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front. Pharmacol. 2014;5:94. DOI: 10.3389/fphar.2014.00094.Mehta N.U., Reddy S.T. Role of hemoglobin/heme scavenger protein hemopexin in atherosclerosis and inflammatory diseases. Curr. Opin. Lipidol. 2015;26(5):384–387. DOI: 10.1097/MOL.0000000000000208.Mehta N.U., Reddy S.T. Role of hemoglobin/heme scavenger protein hemopexin in atherosclerosis and inflammatory diseases. Curr. Opin. Lipidol. 2015;26(5):384–387. DOI: 10.1097/MOL.0000000000000208.Daybanyrova L.V., Shevchenko O.P. Clinical significance levels of C-reactive protein and ceruloplasmin in patients with ischemic heart disease. Wiad Lek. 2015;68(4):517–519.Daybanyrova L.V., Shevchenko O.P. Clinical significance levels of C-reactive protein and ceruloplasmin in patients with ischemic heart disease. Wiad Lek. 2015;68(4):517–519.Dadu R.T., Dodge R., Nambi V., Virani S.S., Hoogeveen R.C., Smith N.L. et al. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ. Heart Fail. 2013;6(5):936–943. DOI: 10.1161/CIRCHEARTFAILURE.113.000270.Dadu R.T., Dodge R., Nambi V., Virani S.S., Hoogeveen R.C., Smith N.L. et al. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ. Heart Fail. 2013;6(5):936–943. DOI: 10.1161/CIRCHEARTFAILURE.113.000270.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Ragino Y.I., Peltek S.E. et al. Proteomic study of blood serum in coronary atherosclerosis. Bull. Exp. Biol. Med. 2017;162(3):343–345. DOI: 10.1007/s10517-017-3611-7.Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Ragino Y.I., Peltek S.E. et al. Proteomic study of blood serum in coronary atherosclerosis. Bull. Exp. Biol. Med. 2017;162(3):343–345. DOI: 10.1007/s10517-017-3611-7.Kim K.H., Ahn Y.H., Ji E.S., Lee J.Y., Kim J.Y., An H.J. et al. Quantitative analysis of low-abundance serological proteins with peptide affinity-based enrichment and pseudo-multiple reaction monitoring by hybrid quadrupole time-of-flight mass spectrometry. Analytica Chimica Acta. 2015;882:38–48. DOI: 10.1016/j.aca.2015.04.033.Kim K.H., Ahn Y.H., Ji E.S., Lee J.Y., Kim J.Y., An H.J. et al. Quantitative analysis of low-abundance serological proteins with peptide affinity-based enrichment and pseudo-multiple reaction monitoring by hybrid quadrupole time-of-flight mass spectrometry. Analytica Chimica Acta. 2015;882:38–48. DOI: 10.1016/j.aca.2015.04.033.Стахнёва Е.М., Каштанова Е.В., Полонская Я.В., Гарбузова (Стрюкова) Е.В., Шрамко В.С., Садовский Е.В. и др. Связь белков острой фазы в крови с наличием нестабильных атеросклеротических бляшек при коронарном атеросклерозе. Профилактическая медицина. 2023;26(8):76–81. DOI: 10.17116/profmed20232608176.Стахнёва Е.М., Каштанова Е.В., Полонская Я.В., Гарбузова (Стрюкова) Е.В., Шрамко В.С., Садовский Е.В. и др. Связь белков острой фазы в крови с наличием нестабильных атеросклеротических бляшек при коронарном атеросклерозе. Профилактическая медицина. 2023;26(8):76–81. DOI: 10.17116/profmed20232608176.Стахнёва Е.М., Мещерякова И.А., Демидов Е.А., Старостин К.В., Садовский Е.В., Пельтек С.Е. и др. Сравнение белкового состава атеросклеротических бляшек коронарных артерий на разных стадиях развития. Молекулярная медицина. 2021;19(5):58–64. DOI: 10.29296/24999490-2021-05-09.Стахнёва Е.М., Мещерякова И.А., Демидов Е.А., Старостин К.В., Садовский Е.В., Пельтек С.Е. и др. Сравнение белкового состава атеросклеротических бляшек коронарных артерий на разных стадиях развития. Молекулярная медицина. 2021;19(5):58–64. DOI: 10.29296/24999490-2021-05-09.

The authors declare that there are no conflicts of interest present.